1
|
Martelli M, Ferreri A, Di Rocco A,
Ansuinelli M and Johnson PWML: Primary mediastinal large B-cell
lymphoma. Crit Rev Oncol Hematol. 113:318–327. 2017. View Article : Google Scholar : PubMed/NCBI
|
2
|
Liu PP, Wang KF, Xia Y, Bi XW, Sun P, Wang
Y, Li ZM and Jiang WQ: Racial patterns of patients with primary
mediastinal large B-cell lymphoma: SEER analysis. Medicine
(Baltimore). 95:e40542016. View Article : Google Scholar : PubMed/NCBI
|
3
|
Jaffe ES, Harris NL, Stein H and Isaacson
PG: Classification of lymphoid neoplasms: The microscope as a tool
for disease discovery. Blood. 112:4384–4399. 2008. View Article : Google Scholar : PubMed/NCBI
|
4
|
Yu Y, Dong X, Tu M and Wang H: Primary
mediastinal large B cell lymphoma. Thorac Cancer. 12:2831–2837.
2021. View Article : Google Scholar : PubMed/NCBI
|
5
|
Zelenetz AD, Gordon LI, Wierda WG,
Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad
LE, Fisher RI, et al: Diffuse Large B-cell lymphoma version 1.2016.
J Natl Compr Canc Netw. 14:196–231. 2016. View Article : Google Scholar : PubMed/NCBI
|
6
|
Vitolo U, Seymour JF, Martelli M,
Illerhaus G, Illidge T, Zucca E, Campo E and Ladetto M; ESMO
Guidelines Committee, : Extranodal diffuse large B-cell lymphoma
(DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 27 (Suppl 5):v91–v102. 2016. View Article : Google Scholar : PubMed/NCBI
|
7
|
Dunleavy K, Pittaluga S, Maeda LS, Advani
R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, et
al: Dose-adjusted EPOCH-rituximab therapy in primary mediastinal
B-cell lymphoma. N Engl J Med. 368:1408–1416. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Savage KJ, Al-Rajhi N, Voss N, Paltiel C,
Klasa R, Gascoyne RD and Connors JM: Favorable outcome of primary
mediastinal large B-cell lymphoma in a single institution: The
British Columbia experience. Ann Oncol. 17:123–130. 2006.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Todeschini G, Secchi S, Morra E, Vitolo U,
Orlandi E, Pasini F, Gallo E, Ambrosetti A, Tecchio C, Tarella C,
et al: Primary mediastinal large B-cell lymphoma (PMLBCL):
Long-term results from a retrospective multicentre Italian
experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br
J Cancer. 90:372–376. 2004. View Article : Google Scholar : PubMed/NCBI
|
10
|
Yang SH, Hsiao LT, Chiou TJ, Yang CF, Yu
YB, Liu CY, Gau JP, Liu JH, Chen PM and Tzeng CH: Rituximab
induction therapy, survival benefits, and the increasing selection
of radiotherapy as the postinduction treatment in patients with
primary mediastinal large B-cell lymphoma. J Chin Med Assoc.
78:400–407. 2015. View Article : Google Scholar : PubMed/NCBI
|
11
|
Aoki T, Izutsu K, Suzuki R, Nakaseko C,
Arima H, Shimada K, Tomita A, Sasaki M, Takizawa J, Mitani K, et
al: Prognostic significance of pleural or pericardial effusion and
the implication of optimal treatment in primary mediastinal large
B-cell lymphoma: A multicenter retrospective study in Japan.
Haematologica. 99:1817–1825. 2014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Zhou H, Xu-Monette ZY, Xiao L, Strati P,
Hagemeister FB, He Y, Chen H, Li Y, Manyam GC, Li Y, et al:
Prognostic factors, therapeutic approaches, and distinct
immunobiologic features in patients with primary mediastinal large
B-cell lymphoma on long-term follow-up. Blood Cancer J. 10:492020.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Harris NL, Jaffe ES, Stein H, Banks PM,
Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter
KC, et al: A revised European-American classification of lymphoid
neoplasms: A proposal from the International Lymphoma Study Group.
Blood. 84:1361–1392. 1994. View Article : Google Scholar : PubMed/NCBI
|
14
|
Oken MM: Toxicity and response criteria of
the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655.
1982. View Article : Google Scholar : PubMed/NCBI
|
15
|
International Non-Hodgkin's Lymphoma
Prognostic Factors Project, . A predictive model for aggressive
non-Hodgkin's lymphoma. N Engl J Med. 329:987–994. 1993. View Article : Google Scholar : PubMed/NCBI
|
16
|
Olweny CL: Cotswolds modification of the
Ann Arbor staging system for Hodgkin's disease. J Clin Oncol.
8:15981990.PubMed/NCBI
|
17
|
Cheson BD, Fisher RI, Barrington SF,
Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance Australasian
Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group;
European Mantle Cell Lymphoma Consortium, ; et al: Recommendations
for initial evaluation, staging, and response assessment of Hodgkin
and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol.
32:3059–3068. 2014. View Article : Google Scholar : PubMed/NCBI
|
18
|
Hasenclever D and Diehl V: A prognostic
score for advanced Hodgkin's disease. International prognostic
factors project on advanced Hodgkin's disease. N Engl J Med.
339:1506–1514. 1998. View Article : Google Scholar : PubMed/NCBI
|
19
|
Pfreundschuh M, Muller C, Zeynalova S,
Kuhnt E, Wiesen MH, Held G, Rixecker T, Poeschel V, Zwick C, Reiser
M, et al: Suboptimal dosing of rituximab in male and female
patients with DLBCL. Blood. 123:640–646. 2014. View Article : Google Scholar : PubMed/NCBI
|
20
|
Mostaghel EA, Martin PS, Mongovin S, Frayo
S, Zhang A, Edlefsen KL, Press OW and Gopal AK: Androgen receptor
expression in mantle cell lymphoma: Potential novel therapeutic
implications. Exp Hematol. 49:34–38.e32. 2017. View Article : Google Scholar : PubMed/NCBI
|
21
|
Talaber G, Yakimchuk K, Guan J, Inzunza J
and Okret S: Inhibition of estrogen biosynthesis enhances lymphoma
growth in mice. Oncotarget. 7:20718–20727. 2016. View Article : Google Scholar : PubMed/NCBI
|
22
|
Jiang S, Zhen H and Jiang H: Role of
radiation therapy in younger and older adults with primary
mediastinal large B cell lymphoma in rituximab Era: A U.S.
Population-based analysis. J Adolesc Young Adult Oncol. 8:623–627.
2019. View Article : Google Scholar : PubMed/NCBI
|
23
|
Takyar J, Raut M, Borse R, Balakumaran A
and Sehgal M: Relapsed/refractory primary mediastinal large B-cell
lymphoma: A structured review of epidemiology, treatment guidelines
and real-world treatment practices. Expert Rev Hematol. 13:275–287.
2020. View Article : Google Scholar : PubMed/NCBI
|
24
|
Armand P, Rodig S, Melnichenko V,
Thieblemont C, Bouabdallah K, Tumyan G, Özcan M, Portino S,
Fogliatto L, Caballero MD, et al: Pembrolizumab in relapsed or
refractory primary mediastinal large B-cell lymphoma. J Clin Oncol.
37:3291–3299. 2019. View Article : Google Scholar : PubMed/NCBI
|
25
|
Tomassetti S, Chen R and Dandapani S: The
role of pembrolizumab in relapsed/refractory primary mediastinal
large B-cell lymphoma. Ther Adv Hematol. 10:20406207198415912019.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Hamlin PA, Portlock CS, Straus DJ, Noy A,
Singer A, Horwitz SM, Oconnor OA, Yahalom J, Zelenetz AD and
Moskowitz CH: Primary mediastinal large B-cell lymphoma: Optimal
therapy and prognostic factor analysis in 141 consecutive patients
treated at Memorial Sloan Kettering from 1980 to 1999. Br J
Haematol. 130:691–699. 2005. View Article : Google Scholar : PubMed/NCBI
|
27
|
Romaguera JE, Rodriguez Diaz-Pavon J,
Carias L, Hagemeister FB, McLaughlin P, Rodriguez MA, Sarris AH,
Younes A, Preti A, Bachier C, et al: Use of the international
prognostic index and the tumor score to detect poor-risk patients
with primary mediastinal large B-cell lymphoma: A study of 37
previously untreated patients. Leuk Lymphoma. 28:295–306. 1998.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Jackson MW, Rusthoven CG, Jones BL, Kamdar
M and Rabinovitch R: Improved survival with radiation therapy in
stage I–II primary mediastinal B cell lymphoma: A surveillance,
epidemiology, and end results database analysis. Int J Radiat Oncol
Biol Phys. 94:126–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
29
|
Jackson MW, Rusthoven CG, Jones BL, Kamdar
M and Rabinovitch R: Improved survival with combined modality
therapy in the modern era for primary mediastinal B-cell lymphoma.
Am J Hematol. 91:476–480. 2016. View Article : Google Scholar : PubMed/NCBI
|
30
|
Held G, Thurner L, Poeschel V, Berdel C,
Ott G, Schmidt C, Viardot A, Borchmann P, Shpilberg O, Nickelsen M,
et al: Role of radiotherapy and dose-densification of R-CHOP in
primary mediastinal B-cell lymphoma: A subgroup analysis of the
unfolder trial of the German Lymphoma Alliance (GLA). J Clin Oncol.
38 (Suppl 15):S80412020. View Article : Google Scholar
|